Mechanism of action
Sevabertinib is a reversible kinase inhibitor of human epidermal growth factor receptor 2 (HER2).
General use cases
- Carcinoma, Non-Small-Cell Lung
- adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 ( ERBB2 ) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
